Express News | Aptevo Therapeutics Has Been Granted Canadian Patent Number 2999138 Titled "CD3 BINDING POLYPEPTIDES (FOR THE TREATMENT OF CANCER)"

Benzinga14:22 ET

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

Lecture to focus on engineering strategies applied to design safe and efficacious bispecific drug candidates, utilizing our proprietary platform technologiesSEATTLE, WA / ACCESSWIRE / May 14, 2024 / A

AccesswireMay 14 08:05 ET

Aptevo Therapeutics Q1 EPS $(9.95) Beats $(12.84) Estimate

Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(9.95) per share which beat the analyst consensus estimate of $(12.84) by 22.51 percent. This is a 76.92 percent increase over losses of

BenzingaMay 8 08:34 ET

Aptevo Therapeutics | 10-Q: Quarterly report

Futu NewsMay 8 08:33 ET · Announcements

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

ptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update.

AccesswireMay 8 08:07 ET

12 Health Care Stocks Moving In Friday's After-Market Session

GainersNeuBase Therapeutics (NASDAQ:NBSE) stock increased by 11.1% to $0.45 during Friday's after-market session. The market value of their outstanding shares is at $1.6 million. Aptevo Therapeutics (

BenzingaMay 3 16:31 ET